Stock CLRB CELLECTAR BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Cellectar Biosciences, Inc.

Equities

CLRB

US15117F8077

Market Closed - Nasdaq
Other stock markets
 21:00:00 24/05/2024 BST 		5-day change 1st Jan Change
3.11 USD +1.63% Intraday chart for Cellectar Biosciences, Inc. -5.76% +12.27%
05-14 Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024
05-14 Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update
AQ
Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
AQ
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
AQ
Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating
MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating
MT
Transcript : Cellectar Biosciences, Inc., 2023 Earnings Call, Mar 27, 2024
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
AQ
Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
AQ
Cellectar Biosciences : Corporate Presentation - March 2024
PU
Cellectar Biosciences to Present at the 36th Annual Roth Conference
AQ
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
AQ
Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
CI
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
AQ
Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study
CI
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
AQ
Cellectar Biosciences Reports Complete Central Nervous System Clearance in Relapsed, Refractory Waldenstrom's Macroglobulinemia Patient
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLRB Stock
  4. News Cellectar Biosciences, Inc.